MedPath

Peking University First Hospital (Peking Univesity First Medical School)

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

303

Active:6
Completed:102

Trial Phases

6 Phases

Early Phase 1:4
Phase 1:8
Phase 2:15
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (198 trials with phase data)• Click on a phase to view related trials

Not Applicable
112 (56.6%)
Phase 4
57 (28.8%)
Phase 2
15 (7.6%)
Phase 1
8 (4.0%)
Early Phase 1
4 (2.0%)
Phase 3
2 (1.0%)

Impact of Antepartum Breast Milk Expression on Breastfeeding Rates in Patients With Gestational Diabetes Mellitus

Not Applicable
Not yet recruiting
Conditions
Gestatiaonl Diabetes Mellitus
First Posted Date
2025-08-19
Last Posted Date
2025-08-19
Lead Sponsor
Peking University First Hospital
Target Recruit Count
212
Registration Number
NCT07128433

Telitacicept for PGNMID: A Single-Arm Study

Not Applicable
Active, not recruiting
Conditions
Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
Interventions
First Posted Date
2025-08-08
Last Posted Date
2025-08-08
Lead Sponsor
Peking University First Hospital
Target Recruit Count
10
Registration Number
NCT07111338
Locations
🇨🇳

Peking University First Hospital, Renal Division, Beijing, Beijing, China

A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients

Not Applicable
Not yet recruiting
Conditions
Renal Artery Stenosis Atherosclerotic
Secondary Hypertension Renal Arterial
Interventions
Diagnostic Test: renal artery fractional flow reserve measurement
Device: renal artery stent
Other: sham stenting
First Posted Date
2025-08-08
Last Posted Date
2025-08-08
Lead Sponsor
Peking University First Hospital
Target Recruit Count
200
Registration Number
NCT07111442
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

Multi-omics Studies of Primary Aldosteronism

Recruiting
Conditions
Primary Aldosteronism
First Posted Date
2025-08-08
Last Posted Date
2025-08-08
Lead Sponsor
Peking University First Hospital
Target Recruit Count
400
Registration Number
NCT07111351
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study

Recruiting
Conditions
Deep Learning
Ultrasound
Bladder Cancer
First Posted Date
2025-08-08
Last Posted Date
2025-08-17
Lead Sponsor
Peking University First Hospital
Target Recruit Count
400
Registration Number
NCT07111364
Locations
🇨🇳

Department of Urology, Peking University First Hospital, Beijing, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 59
  • Next

News

Cellular Senescence Gene Signature Reveals New Biomarkers for Idiopathic Pulmonary Fibrosis

Researchers identified four key cellular senescence-related genes (CDKN2A, VEGFA, SOX2, and FOXO3) that could serve as diagnostic biomarkers for idiopathic pulmonary fibrosis (IPF).

Everest Medicines Reports Promising Phase 1b/2a Results for EVER001 BTK Inhibitor in Primary Membranous Nephropathy

Everest Medicines presented positive Phase 1b/2a trial results for EVER001, a next-generation covalent reversible BTK inhibitor, showing significant efficacy in treating primary membranous nephropathy at the 62nd European Renal Association Congress.

Meta-Analysis Confirms Efficacy of Traditional Chinese Medicine Si-Shen-Wan for Treating IBS-D

A comprehensive meta-analysis of 34 randomized controlled trials involving 2,976 participants has validated the efficacy of Si-Shen-Wan (SSW) in treating diarrhea-predominant irritable bowel syndrome.

VivaVision's VVN461 Shows Promising Results in Phase 2 Trial for Non-Infectious Anterior Uveitis

VivaVision Biotech's dual JAK1/TYK2 inhibitor VVN461 demonstrated non-inferior efficacy to prednisolone acetate in treating non-infectious anterior uveitis in a Phase 2 trial conducted across 10 clinical sites in China.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.